- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
New pain relievers may lower gastrointestinal problems but at increased cost
Everyone's familiar with nonsteroidal anti-inflammatory medications (NSAIDs). These are household names, sold in every drugstore, and consumers use them for headaches, athletic injuries, and other minor aches and pains.
Selective COX-2 Inhibitors NSAIDs target the cyclooxygenase (COX) enzymes, which synthesize prostaglandins.
COX-1 stimulates stomach mucus (which protects the lining of the stomach) while COX-2 is part of the immune response, and produces inflammation. Recently pharmaceutical manufacturers have developed a new class of medications, called selective COX-2 inhibitors, which only work against COX-2. They include:
These selective COX-2 inhibitors are just as effective against pain and inflammation as earlier NSAIDs, but they're much less likely to cause short-term GI problems. "They clearly are easier on the stomach. Whether they also prevent the rare but more serious gastrointestinal side-effects is not clear at this point," says Dr. Abramowicz. "In addition, some studies suggest that Vioxx may lead to a higher rate of heart attacks."
COX-2 inhibitors cost far more than generic NSAIDs, and they've been heavily promoted to physicians (free samples) as well as consumers (catchy jingles on TV). COX-2 usage has grown dramatically over the past few years, and annual U.S. spending on COX-2s now exceeds $6 billion, according to the Wall Street Journal.
Meanwhile, many MCOs have responded by instituting higher copayments for COX-2s compared with generic NSAIDs. One recent study looked at almost 21,000 people with either osteoarthritis or rheumatoid arthritis, enrolled in health plans with tiered formularies. On average, patients in a two-tier plan paid nearly twice as much for COX-2s compared with NSAIDs ($9.67 vs. $5.44) while patients in three-tier plans paid nearly three times as much ($15.35 vs. $5.46.)
These formularies affected member usage patterns, encouraging the use of generic NSAIDs and discouraging COX-2 selective inhibitors.
This study found that even people with serious gastrointestinal comorbidities were significantly less likely to use COX-2s if they were enrolled in a three-tiered plan.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More
